- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04379375
Nudges to Improve Health Behaviors That Limit COVID-19 Spread
Using Behavioral Nudges to Improve Preventive Health Behaviors That Limit COVID-19 Spread
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Provision of signed and dated informed consent form
- Willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
- Has at least 1 risk factor associated with COVID-19 documented in their electronic medical record
- Followed by (i.e., actively receiving care) from targeted MCW specialties (Internal Medicine, OBGYN, Surgery)
- Access to necessary resources for participating in a technology-based activities (i.e., internet access + mobile phone or computer to complete online survey)
- Maintains a personal address where study materials can be shipped and where participant lives full time
Exclusion Criteria:
- Previous COVID-19 diagnosis or positive COVID-19 test result documented in their electronic medical record
- Current participation in another treatment or intervention study associated with COVID-19
- Previous documented Obsessive-Compulsive Disorder diagnosis in their electronic medical record
- Non-English speaker
- Patients hospitalized or incapacitated at onset of potential enrollment
- No access to electronic platform with internet (e.g., smartphone, tablet, computer)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Inertia
Participants simply receive and subsequently have "default" access (i.e., readily and immediately available) to handwashing (HW) materials.
This condition will functionally serve as a control comparison.
As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment.
|
Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
|
|
Experimental: Anchoring
Involves once again providing "default access" to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser.
The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that "overshoots" a desired target rate of 10+ daily HWs.
|
Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand Washing Behavior
Time Frame: 8 weeks post-enrollment
|
Measured via adapted version of a previously validated questionnaire (Hygiene Inventory - 23), which specifically includes (a) 1 item about approximate hand washing frequency on an average day, with response options of whole numbers from 0-29 and an additional option of "30 or more" where higher numbers are generally considered better outcomes, (b) 10 items about hand washing behavior in various contexts, with response options of "1 - Never", "2 - Occasionally", "3 - Usually", and "4 - Always" where higher scores are considered better outcomes, and (c) 1 item about general hand hygiene using antibacterial gel or wipes, with response options of "1 - Never", "2 - Occasionally", "3 - Usually", and "4 - Always" where higher scores are considered better outcomes.
|
8 weeks post-enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Outcomes - General/Internal Medicine
Time Frame: 12 weeks post-enrollment
|
Patient frequency/rate for the following variables measured via electronic medical record: ED visit (respiratory illness/other) ED visit reason (if non-respiratory) Admission (respiratory Illness) Respiratory Illness secondary to COVID19 ICU admission due to respiratory illness ICU admission due to COVID19 Mechanical Respiratory support Duration of Mechanical support (days) Mortality (respiratory Illness/other) |
12 weeks post-enrollment
|
|
Clinical Outcomes - Obstetrics & Gynecology
Time Frame: 12 weeks post-enrollment
|
Patient frequency/rate for the following variables measured via electronic medical record: Respiratory Illness at time of Delivery Pre-delivery COVID19 testing Delivery plan altered due to respiratory illness Miscarriage Preterm labor/birth Preeclampsia Respiratory Illness in newborn Newborn COVID19 testing |
12 weeks post-enrollment
|
|
Clinical Outcomes - Surgery
Time Frame: 12 weeks post-enrollment
|
Patient frequency/rate for the following variables measured via electronic medical record: Respiratory Illness at time of surgery Pre-Operative COVID19 testing Surgery delayed due to respiratory illness Surgery delayed due to COVID19 positive Adverse outcome secondary to delay in surgery Post operative intubation >2 days Post operative unplanned reintubation Post operative pneumonia Post operative respiratory illness secondary to COVID19 |
12 weeks post-enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicholas D Young, PhD, Medical College of Wisconsin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00037864
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruitingCOVID-19 Testing BehaviorsUnited States
Clinical Trials on Nudge
-
Northwestern UniversityNational Institute of Mental Health (NIMH); University of PennsylvaniaCompletedSuicideUnited States
-
Abramson Cancer Center at Penn MedicineAstraZeneca; National Comprehensive Cancer NetworkActive, not recruiting
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
University of PennsylvaniaCompletedControl Condition | How Incentive Receive | How Incentive Holdout | How Incentive Ineligible | How and Why Incentive Receive | How and Why Incentive Holdout | How and Why Incentive IneligibleUnited States
-
Rio de Janeiro State UniversityUniversity of Copenhagen; Oswaldo Cruz Foundation; Universidade Federal do Rio...Withdrawn
-
RANDUniversity of California, Los Angeles; Northwestern University; University of... and other collaboratorsWithdrawnFall | Congestive Heart Failure | Adverse Drug Event | Chronic Kidney FailureUnited States
-
Northwestern UniversityUniversity of California, Los Angeles; National Institute on Aging (NIA); University... and other collaboratorsActive, not recruitingPolypharmacyUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)CompletedCancerUnited States
-
Children's Mercy Hospital Kansas CityNemours Children's Clinic; University of KansasTerminatedType 1 DiabetesUnited States
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Diseases | Coronary Artery Disease | Hypertension | Diabetes Mellitus | Atrial Fibrillation | Hyperlipidemias | Medication Adherence | Adherence, MedicationUnited States